CytoCore's Bio-Marker to be Presented at International Scientific Symposium
News May 05, 2006
CytoCore, Inc., chief research scientist and head of its Medical Advisory Board, Dr. George Gorodeski of University Hospitals Cleveland and Case Western University, will be presenting two papers on the unique apoptotic bio-maker Dr. Gorodeski discovered and licensed to CytoCore, the P2X7, at the 8th. International Symposium on Adenosine and Adenine Nucleotides in Ferrara Italy the last weekend in May.
This Symposium held every 4 years attracts many of the world's top bio-molecular research scientists in the fields of Cellular Receptors, cancer bio-markers and ATP research.
Dr. Gorodeski stated, "We will be presenting two papers on the science behind the inactivation of the P2X7 by its truncated variant counter-part protein receptor, the P2X7-j, and how that relationship between the two appears to abrogate the P2X7 receptor's primary role in the apoptosis process."
"Because the effect was more prevalent in cancer cells, the inhibition of the apoptosis process may be an important mechanism for the enhancement of growth of cancer cells."
"This relationship between the paired receptors, the resulting decline in the apoptosis process, and the increase in cellular cancer growth has been found in the various types of epithelial cells that we have been studied so far."
"As a marker, the P2X7 has demonstrated very accurate sensitivity and specificity results in our initial testing for uterine epithelial cancers, including cervical and endometrial cancers."
"However, because of the widespread expression of the P2X7 receptor in epithelial tissues other the uterus, this mechanism may be more general than we initially thought."
"In fact, in one of the papers that we will present, we will also show a similar trend of results in skin and skin cancers."
"We are now conducting additional research to determine the possible role of the P2X7 as a general and effective screening marker for epithelial tissues."
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Antibody Drug-Conjugate to Target Treatment-Resistant Childhood LeukemiaNews
Researchers have discovered that a protein (5T4) found on the surface of cells contributes to chemotherapy resistance in the most common type of childhood leukaemia. Using a novel approach, early testing shows that targeting the protein with an antibody drug conjugate (ADC) could hold promise in improving treatment.
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018